{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-409865","form_type":"8-K","ticker":"EVMN","cik":"0002044725","company_name":"Evommune, Inc.","filed_at":"2026-10-01T12:01:58+00:00","discovered_at":"2026-10-01T12:05:00.253764+00:00","generated_at":"2026-10-12T14:16:03.553812+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evommune's EVO301 hits Phase 2a primary endpoint in atopic dermatitis: 55% EASI reduction vs 22% placebo","bullets":["Phase 2a trial (n=70; 48 active, 22 placebo) of IV EVO301 5mg/kg at Baseline and Week 4 met its primary endpoint: 55% LS mean EASI reduction at Week 12 vs 22% on placebo (p<0.01).","EASI-50 at Week 12 was 63% for EVO301 vs 23% placebo; EASI-75 was 29% vs 9%; separation appeared by Week 4 (41% vs 18%) and held through Week 8 (50% vs 16%).","Safety: no treatment-related serious or severe adverse events, no discontinuations, no conjunctivitis; treatment-related AEs in 10.4% of EVO301 patients vs 13.6% on placebo.","Biomarkers: ~75% reduction in CCL-17 (TARC) in patients with high baseline TARC, with reductions also in CCL-22, IL-22 and Th1/Th17/Th22 pathway markers.","Subcutaneous Phase 2b dose-ranging trial on track to begin mid-2027; PK profile supports Q4-week dosing with potential every-8-to-12-week maintenance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-409865","json":"https://secwatch.observer/filing/0001193125-26-409865.json","markdown":"https://secwatch.observer/filing/0001193125-26-409865.md","text":"https://secwatch.observer/filing/0001193125-26-409865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/0001193125-26-409865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/evmn-20261001.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:16:03.553812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}